After sudden cardiac death with negative autopsy, clinical screening of relatives identifies a high proportion of inherited arrhythmia syndrome. However, the efficacy of this screening in families not selected by autopsy has never been assessed. We aim to investigate the value of clinical screening in relatives of all subjects who died suddenly before 45 years of age.
S
udden cardiac death (SCD) totals 400 000 deaths per year in the United States. 1 Although most cases are related to coronary artery disease, the incidence of unexplained SCD with negative autopsy exceeds 20% in the United States of America and in England. 2, 3 However, most cases of SCD before the age of 45 remain unexplained. 4 Unexplained SCD in young subjects with no previous symptoms are mainly related to inherited arrhythmias, such as long QT syndrome (LQTS), Brugada syndrome (BrS), or catecholaminergic polymorphic ventricular tachycardia (CPVT). 1 After negative autopsy of the proband, Tan et al 5 demonstrated that the clinical screening of relatives made it possible to provide a diagnosis in 40% of the families. Further confirmation of this study 6 led to the recommendation of such screening in the latest European Society of Cardiology and Heart Rhythm Society guidelines. 7, 8 However, in a large majority of countries, medical autopsy after unexplained SCD is rare, limiting the scope of the latest guidelines. 7, 8 For example, autopsies are frequently unavailable in France, and when performed, they are usually ordered by a judge and then more focused on determining a legal issue in the occurrence of a death. In this context, the value of the clinical screening of relatives after unexplained SCD in a family remains unknown.
The Nantes Center for the Prevention of SCD asked tertiary centers in France to perform clinical and genetic
WHAT IS KNOWN
• Unexplained sudden cardiac deaths in young adults are mainly related to inherited arrhythmia disease.
• After sudden cardiac death in young adults with negative autopsy, the clinical screening of relatives provides a diagnosis in 40% of the families.
WHAT THE STUDY ADDS
• This approach is effective even when an autopsy of the deceased subject is not available.
• A broad screening of relatives, including at least the 2 parents, greatly increases the likelihood of diagnosis in families.
• Systematic tests, including pharmacological challenge, additionally increase the likelihood of diagnosis in families.
screening of the relatives of patients who experienced sudden death before the age of 45 years. In addition to autopsies, we prospectively investigated the performance of clinical screening in the relatives of subjects who suddenly died before the age of 45.
METHODS
After unexplained SCD before the age of 45, an attempt was made to enroll all relatives from May 2009 to December 2014 in a multicenter registry. This study was conducted according to European guidelines for clinical and genetic research. Screening protocol approval was obtained from institutional ethical committees. Informed written consent was obtained from each patient who agreed to participate in the clinical and genetic study. Clinical proband data were collected, as possible, from referring physicians and relatives. When autopsy was performed, the probands whose diagnosis was achievable were excluded from the study.
Familial Screening
Familial screening was first performed in first-degree relatives and then extended as a cascade screening to other relatives if positive. When first-degree relatives were not available for screening, it was performed in more distant relatives (example of a family screening provided in Figure 1) .
Clinical screening included a review of medical history, clinical examination, and baseline ECG. In the absence of diagnosis after this first set of exams, we recommended an exercise test (ET), transthoracic echocardiogram, sodium channel blocker challenge (SCBC) either with ajmaline (1 mg/ kg) or flecainide (2 mg/kg), and an epinephrine test. 8, 9 We also performed a mental stress test to unmask QT prolongation with normal baseline ECG. 10 ECGs performed at baseline, during the stress test, and during the pharmacological test were reviewed by 2 physicians blinded to the clinical and genetic status. All the data were collected in a core database.
The diagnosis criteria adhered to the guidelines of the latest consensus conference. 7, 8 We additionally considered a delta QTm >30 ms during epinephrine or the mental stress test and a delta QTc >30 ms at 3 minutes after the stress test, as sufficient for diagnosis of LQTS. 11, 12 Patients were classified as probably affected if the exams showed abnormalities in favor of the familial diagnosis without reaching diagnosis criteria.
Genetic Analysis
When available, probands were screened for mutations in genes described previously in cardiomyopathy and inherited arrhythmia using Haloplex technology (methods and genes noted in the Data Supplement) as described previously. 13 When putative mutation was identified, family members were screened for familial variant by direct Sanger sequencing. In case of identification of a specific diagnosis in relatives during familial screening, genetic evaluation was proposed for family members according to the last consensus report.
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Statistical Analysis
Statistical analyses were performed with IBM SPSS statistics software (statistical package for the social sciences, version 19; IBM Corp, Armonk, NY). Categorical variables were presented with their numbers and percentages. The χ 2 or Fisher exact test (based on expected frequency) was used to compare categorical variables between groups.
Quantitative variables were presented as mean±SD or median (25th percentile-75th percentile) or median (minimum-maximum) based on distribution. Analysis of continuous variables was performed using a t test or Mann-Whitney U test based on the distribution. Comparisons among families were performed using intrafamilial mean value or median of continuous variable to limit the bias toward family size. A Figure 1 . Familial screening after unexplained sudden cardiac death. Identification of a family (A) affected with Brugada syndrome (BrS) after the unexplained sudden cardiac death (SCD) of a young adult at rest. First-degree relatives were first screened. The BrS was identified after sodium channel blocker challenge (SCBC) in the mother (B) and the sister (C). After identification of the disease, only the biological family members have been screened to enlarge the diagnosis.
2-sided P value of <0.05 was considered to indicate statistical significance in all tests.
RESULTS
Study Population
After at least 1 sudden death in a subject under 45 years, 103 families were referred to the Nantes reference center between May 2009 and December 2014. Of these families, 39 were excluded owing to either refusal or inability to perform family screening. Finally, familial screening was performed in 64 families. (Figure 2) Among the 64 families, 230 family members were screened (age 38±21; 44% men; 3.6±4.1 relatives per family; Table 1 ). Screening involved 1 family member in 25 (39%) families, 2 family members in 9 (14%) families, and at least 3 family members in 30 (47%) families. Among relatives, 151 (67%) were first-degree relatives.
SCD Characteristics
In addition to the 64 probands (mean age, 30.7±14 years), 16 other unexplained SCDs were identified in families (1-6 SCD per family; median 1 [1-1] SCD per family; Table 1) Among these 80 SCDs, thirty-two (40%) SCDs occurred at rest and 14 (17%) during exercise (2 were during swimming). The death circumstances remained unknown in 34 (43%) SCDs. One subject had reported previous syncope, 2 had reported palpitations, and 1 an episode of chest pain.
Autopsies were performed in 18 of 80 (22%) SCDs and were suggestive of a specific diagnosis in 3 (4%) cases. This diagnosis was not further confirmed during family screening (2 cases in families with first-degree relatives affected with BrS, with minor aspect of myocarditis without any ventricular dilatation, inflammation, or scare sufficient to explain SCD; 1 minor ven- For each step, a diagnosed family was excluded from the next step. The details for each examination considered all of the relatives who underwent the examination, including the relatives who belong to families diagnosed during a previous step. CAD indicates coronary artery disease; ET, exercise test; LQTS, long QT syndrome; MRI, magnetic resonance imaging; SCBC, sodium channel blocker challenge; SCD, sudden cardiac death; TTE, transthoracic echocardiogram. *Four relatives suspected to be affected with LQTS, 4 relatives suspected to be affected with BrS (1 not further confirmed); †one patient was previously suspected to be affected on baseline ECG; ‡three patients were previously suspected to be affected on baseline ECG; §three patients were previously suspected to be affected on baseline ECG. tricular hypertrophy in the deceased subject, whereas familial screening remained inconclusive).
Familial Screening
Among the 230 relatives screened, ECG was normal in 165 (71%) of the patients.
LQTS was diagnosed in 7 patients (3%) and suspected in 4 (2%). Diagnosis was further confirmed by epinephrine test in 3 of them (with negative ET) and by ET in one of them.
Four relatives (2%) had a type 2 or 3 Brugada aspect on the ECG, but none had a spontaneous type 1. Diagnosis was further confirmed by SCBC in 3 of them. The last one was finally diagnosed for LQTS.
After the first set of exams (ie, medical history, symptoms, clinical examination, and baseline ECG), 61 (95%) families remained undiagnosed (Figure 2) .
ET was performed in 112 relatives (49%) and revealed significant QT prolongation in 7 (6%), suggested electric ischemia in 5 (4%) with no coronary artery disease demonstrated, and monomorphic and isolated premature ventricular contraction in 9 (8%).
Transthoracic echocardiogram was performed in 124 of 230 (54%) relatives and revealed minor structural heart disease in 19 (15%). It provided a diagnosis in 3 (2%) relatives (1 hypertrophic cardiomyopathy [HCM] and 2 dilated cardiomyopathy).
SCBC was performed in 94 (41%) relatives with no relevant complications. It was considered as positive in 14 cases (15%) and suggestive of BrS in 3 cases (3%).
Epinephrine test was performed in 72 (31%) relatives with nonsustained ventricular arrhythmia observed during 4 tests. It was considered as positive in 13 (18%) relatives, including 7 with a negative ET. The epinephrine test was additionally suggestive of a LQTS in 2 (3%) relatives. ET failed to confirm diagnosis in any of these 2 patients. This second set of exams provided diagnoses in 13 (20%) additional families (Figure 2) .
Magnetic resonance imaging was additionally performed in 17 (7%) relatives but failed to confirm any structural heart disease. Late potentials were performed in 37 relatives (16%) and were positive in 2.
Finally, mental stress tests were performed in 50 relatives (22%). They were considered as positive in 13 (26%) cases and suggestive in 4 (8%). Eleven of them were diagnosed previously as affected with LQTS. The 2 remaining relatives were previously not considered as affected.
Diagnosis in Families
Finally, a diagnosis was identified in 16 (25%) families: 7 BrS, 5 LQTS, 2 HCM, and 2 dilated cardiomyopathy (including 1 laminopathy).
Among the 7 families affected by BrS, 13 SCDs (mean age, 19.3; 67% men; 1-4 SCD per family) occurred, including 6 at rest, 1 during physical activities, and 6 without available case history. All SCDs occurred in patients with affected first-degree relatives. Screening was performed in 3 to 12 relatives per family (median number 5) and positive in 1 to 4 (median number 3; Figure 1 ).
Among the 5 families affected with LQTS, the 5 SCDs occurred at rest (3 at night). Screening was performed in 2 to 23 relatives per family (median number 8.5) and positive in 1 to 8 (median number 3).
Among the families diagnosed with dilated cardiomyopathy, laminopathy, and HCM, the SCD occurred during effort. Screening was performed in 3, 11, and 1 relatives per family and positive in 2, 2, and 1, respectively.
Among the 6 families with several cases of SCD without diagnosis, screening was performed in 1 to 5 relatives per family (median number 1.8) with a 22% rate of complete screening.
Finally, the cascade screening identified 32 relatives affected with the familial disease and 14 probably affected (14/3 BrS, 16/8 LQTS, 1/0 HCM, 0/2 laminopathy, and 1/1 dilated cardiomyopathy with left ventricular noncompaction, respectively; Figure 1 ).
Ten family members were treated with β-blocker therapy for LQTS or HCM. Three family members were implanted with an implantable cardiac defibrillator. A loop recorder was implanted in 1 relative diagnosed with BrS owing to atypical symptoms. After a mean followup of 33 months, no further SCD occurred in relatives.
Predictors of Positive Familial Screening
Clinical and ECG parameters were not associated with diagnosis in relatives. Complete screening (including pharmacological tests) was associated with a higher rate of diagnosis (70% of complete screening in families with positive screening versus 25% in families with negative screening; P<0.0001).
Moreover, the number of screened relatives was strongly associated with diagnosis (8.0±6.2 for families with positive screening versus 2.1±1.4 families with negative screening; P<0.001). The effectiveness of familial screening reached 47% in the families in which at least 3 relatives participated in the screening.
Similar results were observed with first-degree relatives (3.8±3.4 screened relatives for families with positive screening versus 2.0±1.5 for families with negative screening; P<0.005). Among them, the parents seemed to be essential in the diagnostic performance of screening with a diagnostic rate increasing from 3 of 32 (9%) when neither of the 2 parents could be screened to 9 to 22 (41%) when both were screened (P=0.01). The complete results for positive familial screening predictors are presented in Table 1 .
Genetic Analysis
Among the 64 families, genetic testing was performed in 31 families (48%), including 24 probands (37%). It provided identification of 18 rare genetic variations (in ACTN2, CACNA1C, DSC2, DSG2, DSP, KCNH2, KCNQ1, LMNA, MYH7, MYL3, RYR2, and SCN5A genes) in 13 families, including 6 mutations. Variation characteristics are presented in Table 2 .
Genetic testing was then performed in 47 relatives of the 13 families in which a rare genetic variation was identified. Four rare variants (ACTN2, LMNA, KCNQ1, and MYH7) cosegregate with the clinical status of probands and relatives.
Among the 7 families affected with BrS, no mutation in BrS genes was identified.
Among the 5 families affected with LQTS, only 1 mutation in a LQTS gene was identified (in KCNQ1 gene).
DISCUSSION
We present the largest study on familial screening of relatives after unexplained SCD in young adults. In agreement with previous results, we demonstrated that clinical screening of relatives in unselected families provided a diagnosis in 25% of the cases. 15 However, in studies performed after negative autopsy in the proband, diagnostic accuracy was higher, reaching 40% to 53% of the families. 5, 6 The relatively low yield of diagnoses in our study is easily understandable because in France, as in most countries, autopsies are unusual. We attempted to limit this bias by selecting only sudden deaths that occurred before the age of 45, beyond which coronary pathologies prevail. 4 Moreover, despite the fact that we advise tertiary centers in the French network on rare disease to perform a com-plete evaluation of all family members, complete familial evaluations and clinical screening were sometimes limited in our study. We choose to include all family members screened even if only an ECG was available because it reflected a real evaluation of family screening after unexplained SCD.
Interestingly, the diagnostic yield reached 47% in families when at least 3 relatives were screened, which is close to previously published studies 5, 6 and demonstrates that the chances to identify the cause of SCD are directly related to the willingness of family members to participate in screening. Among those relatives, we failed to reveal the clinical characteristics that would identify the families in which SCD is related to genetic diseases. However, we demonstrated the usefulness of pharmacological tests even in patients with normal baseline ECG.
Spectrum of Familial Diagnosis After Unexplained SCD
In the present study, BrS represented 44% of the positive diagnoses, which is clearly higher than the previously described 16% to 17%. 5, 6 Systematic SCBC in relatives, even with normal baseline ECG, can explain this. Once could argue that performance of the SCB challenge in a first step will lead to an unacceptable risk of side effects in otherwise healthy subjects. However, we recently demonstrated the low rate of complications in a large population of familial screening. 16 Moreover, epinephrine tests diagnosed 7 relatives with LQTS who were considered as unaffected after stress tests. In view of these results, it would be advisable to associate SCB challenge and epinephrine test in the initial exams performed during family screening. However, the cost effectiveness of this approach has yet to be evaluated.
Once specific inherited arrhythmia has been identified, the main question will be to evaluate whether the disease is really responsible for SCD. Genetic screening can help to identify inherited arrhythmia, but complex genetic inheritance can limit the yield of such screening. 17, 18 It is clear that if no mutation is found in a family, it will be impossible to definitively conclude because no medical information is usually available for deceased subjects. To analyze whether the identified pathology could explain the SCD, we evaluated the circumstances of each sudden death to estimate whether the diagnosis fit circumstances of the death. Deaths occurred at rest in 26 of 64 probands with available histories. It mostly occurred at rest in BrS and during effort in patients with HCM, which confirmed the imputation of the diagnosis. In comparison, Tan et al 5 described a high proportion of exercise triggered SCD in their study, which principally involved CPVT, arrythmogenic right ventricular cardiomyopathy, and LQTS. The circumstances of SCD in probands, therefore, confirmed the diagnoses in families and its involvement in the SCD of probands (Figure 1) .
Among the 46 relatives affected with the familial pathology, only a few presented genetic rare variants compared with the study by Behr et al 6 . However, in their study, there was a high prevalence of LQTS and CPVT for which the genetic defects were more frequently identified. 6, 18 One of the major interests of family screening is the possibility to identify asymptomatic family members before they present life-threatening arrhythmias and to propose specific treatment according to current guidelines. 7, 19 In our study, 3 patients were implanted with an implantable cardiac defibrillator, and β-blocker treatments were introduced in 10 patients.
Psychological Repercussions and Ethics
Screening is often motivated by the fear of SCD recurrence in a family and the willingness to understand the cause of the accident. However, it is clear that with family screening, there are family members who will be contacted and informed about the risk of SCD for both them and their descendants. It is also clear that when there is an occurrence of SCD in a family, identification of the subject responsible for transmission of the disease could lead to a feeling of guilt and must be discussed and evaluated in all family members before, during, and after screening. However, it has now been demonstrated that when complete evaluation is performed and remains negative, the risk of sudden death is low in a screened subject. 20 So, whatever the results of screening, there will probably be a positive result for family members, but this psychological impact has never been evaluated.
Limitations
There was significant variation in the completeness of the screening from one center to another and then from one family to another. Although it does not allow us to conclude on the most efficient test in the familial screening, it allows us to identify the condition in which the yield of familial diagnosis is increased. It is, therefore, possible that there was an underestimation of the efficacy of such screening.
The large proportion of BrS diagnosed in the families after SCBC could evoke an overestimation of the disease, potentially related to false-positive results of the test. Indeed, the sensitivity and specificity of SCB challenge remains unclear, particularly in the general population. However, as discussed previously, several arguments raised by SCD circumstances led us to consider that BrS was really responsible for the SCD.
As a consequence of this high proportion of BrS, a limited number of affected relatives were treated in our study. Although the eviction of contributing factors in presymptomatic patient may lead to decrease risk of SCD, we are not able to estimate the quantitative benefit of the screening in relatives.
On the contrary, neither arrythmogenic right ventricular cardiomyopathy nor CPVT were identified during the evaluation of the families, despite the fact that transthoracic echocardiogram, stress, and epinephrine tests were performed. Although, no specific conclusion can be drawn on the relatively small number of families, this could be related to regional variability in the prevalence of the diseases as previously shown in the north of Italy.
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Conclusion
Our study demonstrated that clinical screening of the relatives of young subjects who died of unexplained SCD is an effective approach to determine the cause of familial sudden death even when an autopsy of the deceased subject is not available. In view of our results, it seems to be advisable to perform pharmacological challenges in the first step of an evaluation of family members. Additionally, broad screening of relatives, including at least the 2 parents, greatly increases the likelihood of diagnosis in families.
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